SBI Securities’s NeuroSense Therapeutics NRSN Stock Holding History

SBI Securities’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$184	Sell	255 -10	-4%	-$8	﹤0.01%	3350
2026 Q1	$200	Sell	265 -1,190	-82%	-$1.06K	﹤0.01%	3218
2025 Q4	$1.12K	Hold	1,455	–	–	﹤0.01%	2603
2025 Q3	$1.82K	Sell	1,455 -3,000	-67%	-$4.39K	﹤0.01%	2459
2025 Q2	$8.42K	Buy	4,455 +4,280	+2,446%	+$6.2K	﹤0.01%	1777
2025 Q1	$163	Hold	175	–	–	﹤0.01%	3290
2024 Q4	$210	Buy	+175	New	+$201	﹤0.01%	3225

Other funds holding NRSN

YAG

Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

SBI Securities's NRSN Position: Q2 2026 in Review

SBI Securities reduced its NeuroSense Therapeutics (NRSN) stake by 3.8% in Q2 2026, selling an estimated $8 and leaving 255 shares worth $184. The position accounts for ﹤0.01% of the portfolio, ranked #3350.

SBI Securities first reported a position in NRSN in Q4 2024 and has held it in 7 quarters since. The position peaked at $8.42K in Q2 2025. 4 funds tracked by Wall St. Rank hold NRSN as of Q2 2026.

SBI Securities held 255 shares of NeuroSense Therapeutics worth $184 as of Q2 2026.
SBI Securities sold 10 NeuroSense Therapeutics shares in Q2 2026, an estimated $8.
NeuroSense Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3350 holding.
SBI Securities first reported a position in NeuroSense Therapeutics in Q4 2024 and has held it in 7 quarters since.
SBI Securities's NeuroSense Therapeutics position peaked at $8.42K in Q2 2025.
4 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.